e-learning
resources
Copenhagen 2005
Sunday 18.09.2005
Therapeutic options for COPD: present and future
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline
Y. To, S. Kharitonov, I. M. Adcock, P. J. Barnes, K. Ito (London, United Kingdom)
Source:
Annual Congress 2005 - Therapeutic options for COPD: present and future
Session:
Therapeutic options for COPD: present and future
Session type:
Oral Presentation
Number:
215
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. To, S. Kharitonov, I. M. Adcock, P. J. Barnes, K. Ito (London, United Kingdom). Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline. Eur Respir J 2005; 26: Suppl. 49, 215
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment
Source: Eur Respir J 2006; 27: 964-971
Year: 2006
Where current pharmacological therapies fall short in COPD: symptom control is not enough
Source: Eur Respir Rev 2007; 16: 98-104
Year: 2007
Bronchodilatory effects of formoterol in patients with chronic obstructive pulmonary disease (COPD) are not influenced by concomitant corticosteroid use
Source: Eur Respir J 2001; 18: Suppl. 33, 514s
Year: 2001
The role of nebulised budesonide in the treatment of exacerbations of COPD
Source: Eur Respir J 2007; 29: 660-667
Year: 2007
Inhaled corticosteroids and the risk of a first exacerbation in COPD patients
Source: Eur Respir J 2004; 23: 692-697
Year: 2004
The efficacy of formoterol in patients with chronic obstructive pulmonary disease (COPD) is not influenced by concomitant corticosteroid use
Source: Eur Respir J 2001; 18: Suppl. 33, 515s
Year: 2001
Roflumilast with long-acting ?2-agonists for COPD: influence of exacerbation history
Source: Eur Respir J 2011; 38: 553-560
Year: 2011
Effects of inhaled corticosteroids on airway inflammations of different types in patients with chronic obstructive pulmonary disease or asthma in stable phase
Source: Annual Congress 2009 - Aspects of clinical asthma
Year: 2009
Modulation of airway inflammation to prevent exacerbations of COPD
Source: Eur Respir Rev 2005; 14: 78-82
Year: 2005
Formoterol demonstrates bronchodilator efficacy in patients with reversible or poorly reversible chronic obstructive pulmonary disease (COPD), regardless of concomitant corticosteroid use
Source: Eur Respir J 2001; 18: Suppl. 33, 177s
Year: 2001
Inhaled corticosteroids and hospitalisation due to exacerbation of COPD
Source: Eur Respir J 2003; 22: 286-289
Year: 2003
Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter?
Source: Eur Respir J 2003; 21: 260-266
Year: 2003
What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations?
Source: Eur Respir J 2002; 19: 928-935
Year: 2002
Bronchodilator responsiveness in patients with COPD
Source: Eur Respir J 2008; 31: 742-750
Year: 2008
Mucoactive therapy in COPD
Source: Eur Respir Rev 2009; 19: 134-140
Year: 2010
Mechanism by which inhaled bronchodilators prevent exacerbations in chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013
Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2001; 18: Suppl. 33, 146s
Year: 2001
Osteoporosis risk assessment in elderly male patients with COPD who use inhaled corticosteroids
Source: Annual Congress 2006 - COPD therapy
Year: 2006
Mechanisms of exacerbation of respiratory symptoms in patients with COPD
Source: Research Seminar 2006 - Complexity of patients with multiple chronic diseases
Year: 2006
Modern treatment of chronic obstructive pulmonary disease
Source: Eur Respir J 2001; 18: 60S-66S
Year: 2001
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept